Evidence map›Paper›PMID 39362698›Full record

ReviewBMJ global health2024

Learning from the Montreal Protocol to improve the global governance of antimicrobial resistance.

Tina Nanyangwe-Moyo, Gabriel C Fezza, Susan Rogers Van Katwyk, Steven J Hoffman, Arne Ruckert, Samuel Orubu, Mathieu Jp Poirier

Abstract readReview
In one paragraph

Review in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tina Nanyangwe-MoyoGlobal Strategy Lab, York University, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-9175-323X
Gabriel C FezzaGlobal Strategy Lab, York University, Toronto, Ontario, Canada.ORCID http://orcid.org/0009-0009-8847-9864
Susan Rogers Van KatwykGlobal Strategy Lab, York University, Toronto, Ontario, Canada.
Steven J HoffmanGlobal Strategy Lab, York University, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-2064-3711
Arne RuckertGlobal Strategy Lab, York University, Toronto, Ontario, Canada.ORCID http://orcid.org/0009-0000-6416-3560
Samuel OrubuGlobal Strategy Lab, York University, Toronto, Ontario, Canada.
Mathieu Jp PoirierGlobal Strategy Lab, York University, Toronto, Ontario, Canada mathieu.poirier@globalstrategylab.org.ORCID http://orcid.org/0000-0003-3842-0011

Funding

Wellcome Trust
6 · The paper itself

Abstract

The Montreal Protocol has played a critical role in promoting global collective action to phase out the use of ozone-depleting substances, ultimately preventing millions of cases of skin cancer, cataracts and other health issues related to ultraviolet radiation exposure. This success entails transferable lessons for coordinated action required to improve the global governance of other challenges. Like ozone depletion, antimicrobial resistance (AMR) is a challenge of the global commons, requiring coordinated actions across human, animal and environmental sectors. We identify equity, flexibility and accountability as three core governance principles that underlie the success of the protocol and employ the 3-i framework to understand how interests, ideas and institutions contributed to the protocol's success. Equity-promoting strategies consisted of an inclusive negotiation process, supporting developing countries with multilateral funding and a progressive compliance model. Flexibility was built into the protocol through the development of country-specific strategies, reorienting incentive structures for industry and facilitating regular amendments in response to emerging scientific evidence. Accountability was promoted by mobilising public advocacy, establishing targets and enforcement mechanisms and conducting independent scientific and technical assessments. Applying our proposed principles presents an opportunity to improve the global governance of AMR. Finally, we acknowledge limitations to our analysis, including our focus on a single environmental treaty, significantly greater funding requirements and multifacetted stakeholder involvement in the case of AMR, differing market and incentives structures in antibiotic development and distribution, and ethical concerns with using trade restrictions as a policy tool.

Indexed as

Global HealthAnti-Bacterial AgentsDrug Resistance, MicrobialHumansInternational CooperationAnti-Bacterial AgentsEnvironmental healthGlobal HealthHealth policyPublic Health

Identifiers

PMID39362698
PMCPMC11459323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.